Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcturus Leaps On COVID-19 Trials And Investor Interest In mRNA

Share Price Soars By 68%

Executive Summary

Singapore has granted approval for a Phase I/II trial of Arcturus’s next generation mRNA COVID-19 vaccine candidates, hot on the heels of a similar approval from Vietnam earlier this week. The biotech’s share price duly rocketed, but there may be more at play.

You may also be interested in...



More Candidate COVID-19 Vaccines Expected To Enter WHO’s Global Trial

A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.

Biotech Foundations: Networks And Lab Space Are As Crucial As Funding

BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies. 

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel